A large number of patients with small cell lung cancer are diagnosed with atypical neuroendocrine or non-neuroendocrine subtypes, which is an aggressive malignancy characterized by rapid progression, early metastasis, and molecular heterogeneity.
Abstract
: Background: Small cell lung cancer (SCLC) is an aggressive malignancy characterized by rapid progression, early metastasis, and molecular heterogeneity. Neuroendocrine (NE) and non-neuroendocrine (non-NE) SCLC subtypes differ in transcriptional programs related to Achaete-scute homolog 1 (ASCL1), Neurogenic differentiation 1 (NEUROD1), POU domain, class 2, transcription factor 3 (POU2F3)
Evaluated DLL3 expression and CD8+ tumor‐infiltrating lymphocytes (TILs) infiltration in LCNEC and investigated their clinical significance and association with tarlatamab efficacy.
S. Kaneko, Naoki Furuya, Y. Sugiura et al.· Thoracic Cancer· 0 citations
A single-nucleus analysis of 189 colorectal tumors found that early-onset cancers differ from those in older patients in cellular composition, gene signaling, and expression of regulatory RNAs. The findings offer clues to the biology of early-onset disease, but further studies are needed to determine whether these mole...
Findings establish SLCO1B3 as an independent prognostic biomarker and functional driver that sustains stemness and malignant phenotypes in HNSCC, providing a rationale for its therapeutic targeting.
Tissue biomarkers may improve risk stratification in locally advanced cervical cancer before definitive concurrent chemoradiotherapy (CCRT). We evaluated pretreatment expression of chromobox 4 (CBX4), NADPH oxidase 4 (NOX4), specificity protein 1 (SP1), and copper transporter 1 (CTR1) in relation to CCRT response and o...
Xianyu Pang, Xi-Yun Qin, Li-Lin Que et al.· Cancer Medicine· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.